Goldman Sachs Maintains Sell on FIGS, Raises Price Target to $6.25
Goldman Sachs analyst Brooke Roach maintains FIGS (NYSE:FIGS) with a Sell and raises the price target from $5.5 to $6.25.
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
Credit Suisse Maintains Outperform on FIGS, Lowers Price Target to $10
Credit Suisse analyst Michael Binetti maintains FIGS (NYSE:FIGS) with a Outperform and lowers the price target from $12 to $10.
Telsey Advisory Group Maintains Outperform on FIGS, Lowers Price Target to $11
Telsey Advisory Group analyst Dana Telsey maintains FIGS (NYSE:FIGS) with a Outperform and lowers the price target from $12 to $11.
Telsey Advisory Group Maintains Outperform on FIGS, Raises Price Target to $12
Telsey Advisory Group analyst Dana Telsey maintains FIGS (NYSE:FIGS) with a Outperform and raises the price target from $9 to $12.
Raymond James Maintains Outperform on FIGS, Raises Price Target to $10
Raymond James analyst Rick Paterson maintains FIGS (NYSE:FIGS) with a Outperform and raises the price target from $8 to $10.
Raymond James Downgrades FIGS to Outperform, Lowers Price Target to $8
Raymond James analyst Rick Paterson downgrades FIGS (NYSE:FIGS) from Strong Buy to Outperform and lowers the price target from $12 to $8.
Morgan Stanley Maintains Equal-Weight on FIGS, Lowers Price Target to $10
Morgan Stanley analyst Lauren Schenk maintains FIGS (NYSE:FIGS) with a Equal-Weight and lowers the price target from $11 to $10.
Short Seller Says They’re Vindicated (Again) On This Defensive Stock
In a short report initiated April, 1 2020 with two accompanying updates, Spruce Point Capital Management warned that…